Navigation Links
Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
Date:8/2/2012

SAN DIEGO, Aug. 2, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the second quarter and six months ended June 30, 2012.

Net product revenue in the second quarter was $11.1 million, an increase of $3.1 million, or 38%, from the first quarter of 2012. This increase marks the company's sixth consecutive quarter of net product revenue growth since launching OFIRMEV® (acetaminophen) injection in January 2011.

A summary of the recent highlights and events for the company include the following:

  • Net product revenue of $11.1 million for the second quarter of 2012 and $19.1 million for the six months ended June 30, 2012
  • A 40% increase in the customer base for OFIRMEV in the first half of 2012 to nearly 3,200 unique customers at June 30, 2012
  • A New Drug Submission for OFIRMEV submitted to Health Canada in July 2012
  •  

    "OFIRMEV demand continues to accelerate, and exceeded our expectations in the second quarter of this year. I'm very pleased with how our sales team is executing on our strategy. Our customer base is growing rapidly, as physicians continue to embrace OFIRMEV as the foundation of a multi-modal approach to managing acute pain," said Ted Schroeder, President and CEO of Cadence. "Since launch, we believe that between 1.2 million and 1.5 million patients in the United States have been treated with OFIRMEV."

    Financial Results
    For the three months ended June 30, 2012, Cadence reported net product revenue of $11.1 million, an increase of $9.4 million from the $1.7 million of net product revenue reported for the three months ended June 30, 2011. For the six months ended June 30, 20
    '/>"/>

    SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
    2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
    3. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
    4. Optimer Pharmaceuticals Reports Second Quarter 2012 Financial Results
    5. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    6. Global Biopharmaceuticals Market 2011-2015
    7. Patient Advocate Foundation and Jazz Pharmaceuticals Announce Partnership for Narcolepsy CareLine
    8. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
    9. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
    10. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
    11. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/5/2015)... -- DuPont (NYSE: DD ) announced that at ... today in New York , DuPont ... strategy, progress and plans to accelerate growth in the ... the company,s leading position in high-value advanced materials is ... DuPont. Discussing the company,s Advanced Materials segments, ...
    (Date:3/5/2015)... Springs, FL (PRWEB) March 05, 2015 ... Damm for the position of Vice President of Managed ... managed care relationships for one of the nation’s leading ... brings more than 15 years of specialty pharmacy and ... Damm worked with Raptor Pharmaceuticals, Vertex Pharmaceuticals, and Pfizer. ...
    (Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... of the "Mature Biotech Outlook 2015: New Therapy ... their offering. All biotech companies - ... (CELG), in past year, have given a positive return ... companies have been able to select therapy/niche indication where ...
    (Date:3/4/2015)... , March 4, 2015 PDL BioPharma, Inc. (PDL) (NASDAQ: ... rate for the: , 3.75% Convertible Senior Notes ... of common stock per $1,000 principal amount or approximately $5.72 ... rate for the note is adjusted in connection with the ... 2015, to all stockholders who own shares of PDL on ...
    Breaking Biology Technology:DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 2DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 3DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 4BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
    ... Delivers Solid Financial Performance While Building for the Future, ... GENZ ) today reported strong sales and profit growth ... commercial and clinical,programs., Revenue increased 25 percent to ... quarter. The increase was driven by,growth across all areas ...
    ... TORONTO, July 23 /PRNewswire-FirstCall/ - Roche,(SWX: ROG) and ... two,companies have signed a definitive agreement for Roche ... price of approximately C$191 million. ARIUS is,the developer ... identifies and selects antibodies based on their functional,ability ...
    ... of,Directors of BD (Becton, Dickinson and Company) (NYSE: ... per common share. The dividend will be,payable on September ... 2008.,The indicated annual dividend rate is $1.14 per share., ... medical technology company that develops,manufactures and sells medical devices, ...
    Cached Biology Technology:Genzyme Reports Strong Second-Quarter Growth 2Genzyme Reports Strong Second-Quarter Growth 3Genzyme Reports Strong Second-Quarter Growth 4Genzyme Reports Strong Second-Quarter Growth 5Genzyme Reports Strong Second-Quarter Growth 6Genzyme Reports Strong Second-Quarter Growth 7Genzyme Reports Strong Second-Quarter Growth 8Genzyme Reports Strong Second-Quarter Growth 9Genzyme Reports Strong Second-Quarter Growth 10Genzyme Reports Strong Second-Quarter Growth 11Genzyme Reports Strong Second-Quarter Growth 12Genzyme Reports Strong Second-Quarter Growth 13Genzyme Reports Strong Second-Quarter Growth 14Genzyme Reports Strong Second-Quarter Growth 15Genzyme Reports Strong Second-Quarter Growth 16Genzyme Reports Strong Second-Quarter Growth 17Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 2Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 3Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 4
    (Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
    (Date:1/22/2015)... (NASDAQ: NXTD and NXTDW) a biometric authentication company focused ... the Wocket™ smart wallet at CES 2015 in Las Vegas ... of the "11 Hot Products at CES" in a review published in ... by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
    (Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
    Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
    ... pulp is wood. However, growing demand in the paper industry, ... sector to turn to other sources of raw materials, such ... This residue, obtained after crushing of the cane, is already ... (in South America and India for example, where it represents ...
    ... first biochemical marker linked to sleep loss, an enzyme in ... deprivation is prolonged. , Researchers hope to make amylase the ... and treatment of sleep disorders and may one day help ... a car or in other dangerous contexts. , ...
    ... Lee Dequeant, Ph.D., a Predoctoral Researcher at the Stowers ... Institute Investigator and an investigator with the Howard Hughes ... on a paper that identifies a network of cyclic ... spine formation in the embryo. , The ...
    Cached Biology News:Developing uses for sugar-cane bagasse: Biotechnology applied to the paper industry 2Developing uses for sugar-cane bagasse: Biotechnology applied to the paper industry 3First biomarker for human sleepiness identified in fruit flies 2First biomarker for human sleepiness identified in fruit flies 3
    ... of a Hybridizer and UV Crosslinker (254nm UV) ... , This unique, new design for the ... one location , Hybridizer and Crosslinker portions ... , The Crosslinker is also available as ...
    Oven mesh sheets, large, 23 x 23cm, pack of 5...
    ... Effectively condenses and traps a wide variety ... vacuum pump oil. Easy-to-use glass condensation flask (GCF400) ... self contained jar for easy draining. Rapid cooling ... remove glass flask for quick solvent changes ...
    ... Lambda Protein Phosphatase ... Mn2+-dependent protein phosphatase with ... threonine and tyrosine residues. ... amino-acid product of the ...
    Biology Products: